BioCentury
ARTICLE | Financial News

Acceleron, Stemline price upsized follow-ons

January 18, 2019 8:41 PM UTC

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch.

Acceleron said Jan. 16 that it raised $230 million through the sale of 5.3 million shares at $43. The price is a 7% discount to Acceleron's closing price of $46.44 on Jan. 14, when it proposed after market hours to raise $200 million. Its shares slipped $2.52 to $43.92 on Jan 15, and lost another $1.11 to $42.81 on Jan. 16...